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Objective: In autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED) defects in the autoimmune regulator gene lead to impaired
immunotolerance. We explored the effects of immunodeficiency and endocrinopathies
on gynecologic health in patients with APECED.
Design: Cross-sectional cohort study combined with longitudinal follow-up data.
Methods:We carried out a gynecologic evaluation, pelvic ultrasound, and laboratory and
microbiologic assessment in 19 women with APECED. Retrospective data were collected
from previous study visits and hospital records.
Results: The study subjects’ median age was 42.6 years (range, 16.7-65.5). Sixteen
patients (84%) had premature ovarian insufficiency, diagnosed at the median age of 16.5
years; 75% of them used currently either combined contraception or hormonal
replacement therapy. In 76% of women, the morphology and size of the uterus were
determined normal for age, menopausal status, and current hormonal therapy. Fifteen
pat ients (79%) had pr imary adrenal insufficiency; three of them used
dehydroepiandrosterone substitution. All androgen concentrations were under the
detection limit in 11 patients (58%). Genital infections were detected in nine patients
(47%); most of them were asymptomatic. Gynecologic C. albicans infection was detected
in four patients (21%); one of the strains was resistant to azoles. Five patients (26%) had
human papillomavirus infection, three of which were high-risk subtypes. Cervical cell
atypia was detected in one patient. No correlation between genital infections and anti-
cytokine autoantibodies was found.n.org November 2021 | Volume 12 | Article 7841951
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levels in over half of the patients. Asymptomatic genital infections, but not cervical cell
atypia, were common in female patients with APECED.Keywords: endocrine, autoimmunity, female, premature ovarian insufficiency, ovary, androgen, APS-1INTRODUCTION
Autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED), also called autoimmune polyendocrine
syndrome type I (APS-I), is a rare disorder arising from
mutations in the autoimmune regulator (AIRE) gene (1).
Mutations in AIRE cause disturbances in T cell maturation and
development of central tolerance in the thymus, leading to
autoimmune manifestations (2). The classic triad of APECED
is characterized by hypoparathyroidism (HP), primary
adrenocortical insufficiency (PAI), and chronic mucocutaneous
candidiasis (CMC). Other potential disease manifestations
include e.g. premature ovarian insufficiency (POI),
hypothyroidism, malabsorption, and autoimmune hepatitis (3).
CMC is the most common and often one of the first
manifestations in APECED (4). CMC typically manifests at
oral mucosa, but may also affect the mucosa of the esophagus,
intestine, or genital tract (5). Patients need preventive, long-term,
or intermittent antifungal medications, and consequently
Candida albicans strains may develop resistance to azoles (6).
Studies in APECED have found oral CMC to correlate with
circulating antibodies against Th17 related cytokines IL-22 and
IL-17F (7, 8). These anti-cytokine autoantibodies are common in
patients with APECED even before any clinical disease
manifestations develop (5, 9, 10). However, the effects of anti-
cytokine autoantibodies remain largely unknown. Oral CMC can
predispose to oral squamous cell carcinoma (11), but it is
unknown if CMC may also predispose to cell atypia on other
mucosal surfaces, such as genital mucosa. Furthermore, it is not
known whether patients with APECED have increased risk for
other gynecologic infections including human papillomavirus
(HPV) infections and consequently for cervical neoplasms.
In addition to vulnerability to infections, also certain
endocrinopathies including POI and PAI, have potential effects
on gynecologic health in female patients with APECED (12). In
Finnish female patients with APECED, POI is the third most
common endocrinopathy, manifesting in 70% at the median age
of 16 years (12). In other APECED cohorts, the prevalence of
POI varies from 9% to 71% (5, 13–15). POI leads to
hypoestrogenism and lack of ovarian androgens (16). PAI is
found in 22-83% of patients with APECED resulting in lack of
adrenal androgens (5, 13–15). Long-term hormone replacement
therapy (HRT) is needed to prevent consequences of
hypoestrogenism (17). However, studies on adrenal androgen
substitution have been controversial (18, 19). To our knowledge,
no study has evaluated the effects of POI and PAI on gynecologic
health in patients with APECED.
In this study with cross-sectional evaluation combined with
longitudinal follow-up data, we describe in detail the patients’n.org 2gynecologic health including hormonal state, pelvic ultrasound,
cell and microbe samples of cervix and vagina, and presence of
autoantibodies against cytokines. We aimed to clarify the effects
of immunodeficiency and endocrinopathies on gynecologic
health in APECED in order to guide patient management.MATERIALS AND METHODS
Patients
Patients were identified from the large Finnish cohort of over 90
patients with APECED (4, 20). All living female patients aged 11
years and older (n=33) were invited to participate in the study, 20
(61%) of them consented. One patient was excluded from final
analysis due to prepubertal status based on clinical assessment and
laboratory parameters. Eleven patients (11/19, 58%) had also
participated in an earlier gynecologic study in 1995, allowing
longitudinal data evaluation. Informed written consent was
obtained from study participants or their guardians (subjects <18
years). Ethical approval was obtained from the Research Ethics
Committee of the Hospital District of Helsinki and Uusimaa.
Clinical Assessments
Patients were interviewed for detailed medical history and
measured for height (to the nearest 0.1 cm) and weight (in
light clothing to the nearest 0.1 kg). Patients underwent a
complete gynecologic examination and pelvic ultrasound (GE
Healthcare Voluson S6), performed by gynecologist (EH).
Clinical estrogenization of external genitalia and vagina were
estimated. Pubertal status was determined according to Tanner’s
scale for breast development and pubic hair (21). Morphology of
the uterus and ovaries was assessed by ultrasound and compared
with age and menopausal status-based reference values (22).
Normal size of the uterus was considered as a sign of adequate
estrogenization. The maximum anterior-posterior distance
measured in the mid-portion of the uterine body on a sagittal
view, and median length of the uterine corpus, measured from
the fundus to the internal orifice of the uterus on a sagittal view,
were determined (23, 24). Antral follicle count was determined
when technically possible and considered normal if it was
between 10th and 90th percentiles of age-specific normal
values (25).
Hospital records were reviewed for pubertal development,
development of POI, ferti l ity, previous gynecologic
examinations, and gynecologic surgical operations. POI was
diagnosed if the patient had not reached stage 2 of breast
development by age 13 years or menarche by 15 years or she
had POI symptoms with secondary amenorrhea for 4 months or,
in the case with primary or secondary amenorrhea, if follicle-November 2021 | Volume 12 | Article 784195
Saari et al. Gynecologic Health in APECEDstimulating hormone (FSH) was over 40 IU/L before the age of
40 years (16, 26). APECED manifestations (CMC, HP, PAI,
diabetes, growth hormone deficiency, hypothyroidism, alopecia,
asplenia, constipation, diarrhea, enamel hypoplasia, gastritis,
hepatitis, keratoconjunctivitis, nephritis, oral squamous
carcinoma, rash with fever, vitiligo) and their age of onset,
were reviewed.Hormone and Autoantibody Assays
Blood samples were obtained without fasting. Serum
concentrations of Anti-Müllerian hormone (AMH), FSH,
lute iniz ing hormone (LH), es tradio l , testosterone,
androstenedione, and dehydroepiandrosterone (DHEAS) were
measured and interpreted regarding phase of cycle or use of
hormonal therapy.
AMH was quantitated with an electrochemiluminometric
assay on a cobase 411 automatic immunoanalyzer (Elecsys
AMH Plus, Roche Diagnostics). Limit of detection (LoD) was
0.01 µg/L and limit of quantitation (LoQ) 0.03 µg/L. Intra-assay
coefficient of variations (CV%) was < 2% and inter-assay
CV% <5% in the range 0.2–19 µg/L of AMH. Age-specific
limits of AMH were applied (27). LH and FSH concentrations
were measured using an electrochemiluminescence
immunoassay (Abbott Diagnostics). Method for LH had a LoQ
of 0.07 IU/L; intra-assay CV% was 3% and inter-assay CV% 7%.
Method for FSH had a LoQ of 0.3 IU/L; intra-assay CV% was 7%
and inter-assay CV% 7%.
Serum estradiol, androstenedione, and testosterone were
extracted with liquid-liquid extraction using diethyl ether.
Androstenedione sample extracts were analyzed on a liquid
chromatography-tandem mass spectrometry system (LC-MS/
MS) comprising a TQ5500 triple quadrupole mass
spectrometer (AB Sciex) and an Agilent Technologies (Santa
Clara) series 1200 HPLC system with a binary pump. The LC-
MS/MS method for androstenedione had a LoQ of 0.1 nmol/L;
inter-assay CV% at 3.2, 8.0, and 19 nmol/L was 5.5%, 6.4%, and
8.1%, respectively. Testosterone sample extracts were analyzed
on an LC-MS/MS system comprising an API3000 triple
quadrupole mass spectrometer (AB Sciex) and an Agilent
Technologies (Santa Clara) series 1100 HPLC system with a
binary pump. The LC-MS/MS method for testosterone had a
LoQ of 0.2 nmol/L; inter-assay CV% at 4.7, 15.8, and 25.1 nmol/L
was 5.2%, 4.6%, and 5.3%, respectively. Estradiol was quantitated
by LC-MS/MS using a TQ5500 mass spectrometer (AB Sciex).
The between-run CV% were 4.5-5.7% for serum samples at
concentrations of 317-898 pmol/L and the detection limit was
0.01 nmol/L (28). DHEAS sample extracts were measured using
a direct chemiluminescent immunoassay (Siemens Atellica OM
1600 Analyzer). The detection limit was 0.08 µmol/L; intra-assay
CV% was 7%, and inter-assay CV% 7%.
Autoantibodies against interferon-a (IFN-a), interferon-g
(IFN-g), interleukin-17A (IL-17A), interleukin-17F (IL-17F),
and interleukin-22 (IL-22) were detected by ELISA and by flow
cytometric bead array (Luminex analyzer) in an accredited
laboratory as previously described (7, 29).Frontiers in Endocrinology | www.frontiersin.org 3Cellular and Microbe Samples
Candida culture of vulva and vagina, cervical HPV tests, and
PAP smears were obtained. C. albicans swabs were cultured in
CHROM-agar dish at 37°C for one week. Growth was identified
with the bioMerieux VITEK-MSMaldi-tof method. Resistance of
C. albicans to medications was tested with Etest (bioMerieux). If
the C. albicans population was resistant to fluconazole, resistance
to other fungal medication (voriconazole, amphotericin B, and
micafungin) was tested. In Etest, C. albicans was mixed with
0.9% NaCl to cultivate a mixture of 1.2 Macfarland. The mixture
was spread to RPMI-dish, where E-test strips were added. MIC-
value was assessed on two consecutive days.
Cervical samples for HPV tests were taken by APTIMA
cervical collection and transport KIT. HPV subtypes were
analyzed by PCR and Luminex suspension array technology
(30). The test detects 15 high-risk HPV types, six potentially
high-risk types, and 19 low-risk HPV types. Pap smears were
analyzed using standard clinical protocols.Statistical Analysis
Median (range) was used to report the results. Mann-Whitney U
or Spearman correlation test was used for continuous variables
and Fisher’s exact test for categorical variables. A P value under
0.05 was considered statistically significant. IBM SPSS statistics
version 25 was used for statistical analysis.RESULTS
Patient Characteristics and
Gynecologic History
The median age of the 19 study participants was 42.6 years
(range, 16.7–65.5). All patients had biallelic AIRE mutations.
Fifteen patients (79%) were homozygous for the Finnish major
mutation c.769C>T (p.Arg257Ter) in the AIRE. Three patients
had the major mutation compounded with c.932G>A
(p.Cys311Tyr) (n=1), c.967_979del13 (p.Leu323fs) (n=1), or
c.137C>G (p.Thr46Arg) (n=1). One patient had c.901G>A
(p.Val301Met) and an intronic variant c.996-17G>A in the AIRE.
The cohort characteristics are presented in Tables 1, 2.
Fourteen patients (74%) had gone through spontaneous
pubertal development. In five patients (26%), HRT had been
used to induce or to complete pubertal development and to
induce menarche. Altogether 16 patients (84%) had developed
POI at the median age of 16.5 years (11.3–36.5). Ten patients
(63%) with POI currently used HRT, and two used combined
contraception (Table 2). At the time of evaluation, five women
were considered postmenopausal (Table 1). PAI was diagnosed
in 15 patients (79%) in the median age of 10.8 years (2.5–32.9),
and three of them (20%) used dehydroepiandrosterone (DHEA)
substitution. None of the patients currently used testosterone
therapy. Three patients (16%) had used fluoxymesterone to
induce pubic hair growth from the median age of 11.4. OnlyNovember 2021 | Volume 12 | Article 784195
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Eight patients (42%) had been pregnant (Table 1).
Three patients (16%) had undergone gynecological surgery;
abdominal hysterectomy with bilateral salpingo-oophorectomy
(n=1), hysterectomy (n=1), and uterine artery embolization
(n=1). Indications were excessive gynecological bleeding,
miscarriage, and uterine leiomyomas, respectively.Frontiers in Endocrinology | www.frontiersin.org 4Gynecologic Status
At clinical evaluation, all patients had completed pubertal
development. Their median height was 161.0 cm (151.2-
174.0 cm; Table 2). All had normal breast development. Pubic
hair was absent in seven patients (37%): all of them had PAI and
had previously had at least Tanner stage 2 for pubic hair growth
and none of them currently used DHEA substitution.TABLE 2 | Patient characteristics, state of hormonal replacement therapy, and ultra-sound measurements at the time of appointment in the 19 patients with APECED.
Variable Median/n Range/%
Height (cm) 161.0 151.2 – 174.0
Height SDS -1.1 -2.9 – + 1.3
Weight (kg) 62.0 34.7 – 100.0
BMI (kg/m2) 23.2 13.8 – 42.7
Underweight (< 18.5) 4 21%
Normal weight (18.5–25) 10 53%
Overweight (> 25) 5 26%
Spontaneous menstrual cycle at study visit 2 11%
Current hormonal therapy in use 12 63%
Combined contraception 2 11%
Systemic HRT a 10 53%
Transdermal estrogen + oral progesterone 1 10%
Oral estrogen + oral progesterone 6 60%
Oral estrogen + levonorgestrel releasing intrauterine device 1 10%
Oral estrogen without progesterone 2 20%
Vaginal estrogen only 1 8%
Normal size of the of uterus b (n=17) c 13 76%
Abnormal size of the uterus b (n=17) c 4 24%
AP of uterus corpus (mm) (n=17) 32.0 15.0 – 49.0
Length of uterus corpus (mm) (n=15) 39.0 30.0 – 59.0
Ovaries identifiable (n=18) d 12 67%
Ovarian AFC in a normal range 2 17%November 2021 | Volume 12 |HRT, hormone replacement therapy; AP, anterior posterior; AFC, antral follicle count.
asystemic HRT and vaginal estrogen, n=3 (16%); bassessed in relation to patient’s age, phase of menstrual cycle, menopausal status, and HRT (21); cuterus surgically removed from 2
patients; dovaries surgically removed from 1 patient, ovaries identifiable in 12 patients.TABLE 1 | History of pubertal development, manifestations of APECED and pregnancies in the 19 patients with APECED.
Characteristic Median/n Range/%
Age at study visit (years) 42.6 16.7 – 65.5
Age at stage 2 of breast development 11.9 10.6 – 17.7
Age at stage 2 of pubic hair growth 13.1 10.6 – 16.7
Age at menarche
Spontaneous (n=14) 13.8 11.0 – 15.5
Medically induced (n=5) 17.7 14.3 – 18.5
Age at POIa (n=16) 16.5 11.3 – 36.5
Age at menopause/discontinuation of HRT
Physiological menopause (n=1) 48.3 –
Age at the discontinuation of HRT (n=4) 51.4 47.3 – 53.5





Ever been pregnant 8 42%
Number of pregnancies 10
Spontaneous 5
Ovum donation 5ArPOI, premature ovarian insufficiency; PAI, primary adrenocortical insufficiency; HP, hypoparathyroidism; CMC, chronic mucocutaneous candidiasis.
aDiagnostic criterion: delayed puberty (patient has not reached stage 2 of breast development by the age of 13 years or menarche by the age of 15 years) or POI symptoms with
amenorrhea and/or FSH over 40 IU/L under the age of 40 years.ticle 784195
Saari et al. Gynecologic Health in APECEDExternal genitalia and vaginal epithelium were considered
normal in 11 patients (58%). Vulvovaginal atrophy was found in
five patients (26%). Yeast infection and unspecific vaginitis was
clinically suspected in three and one patient, respectively.
Pelvic ultrasound was performed vaginally in 18 patients and
abdominally in one patient (Table 2). In 13 (13/17, 76%) women,
the morphology and size of the uterus were determined normal
for age, stage of menstrual cycle, menopausal status, and current
hormonal therapy. The four patients with uterus size below
reference values were currently using HRT. No ovarianFrontiers in Endocrinology | www.frontiersin.org 5pathology was diagnosed in 12 patients with identifiable
ovaries. Consistently with POI, antral follicle count was
diminished in most patients (10/12, 83%).
Hormonal Levels
FSH, LH, and estradiol levels were consistent with the cycle phase
or hormonal treatment (data not shown). AMH was below the
detection limit in 15/19 patients, all with POI or menopausal
(Figure 1A). AMH was subnormal in one female (0.27 µg/L) who
still had spontaneous cycles reflecting the depletion of ovarianA B
FIGURE 1 | Ovarian and adrenocortical hormones in 19 female patients with APECED. (A) Anti-Müllerian hormone (AMH), androstenedione, and testosterone levels
in relation to ovarian function and hormonal replacement therapy (HRT). (B) Dehydroepiandrosteronesulfate (DHEAS) levels in relation to the presence of primary
adrenocortical insufficiency (PAI) and use of dehydroepiandrosterone (DHEA) substitution. Values in transparent markings are considered to be within the normal
range.November 2021 | Volume 12 | Article 784195
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two patients with POI and regular HRT substitution.
Androgen levels were low in patients with APECED
(Figures 1A, B). Testosterone, androstenedione, and DHEAS
were below the detection limit in 67%, 63%, and 68% of the
patients, respectively. DHEAS was below the detection limit or
low normal in all patients with PAI who did not have DHEA
substitution (Figure 1B). All androgens were below the detection
limit in 11 patients (58%).Genital Infections and Cervical Cell Atypia
History of genital infections and results of the previous and
current gynecologic microbial and Pap smear samples are
presented in Table 3. Only two patients did not report any
previous genital infections. Seventeen patients (89%) had
experienced at least one previous genital C. albicans infection.
Six (35%) of them reported recurrent genital C. albicans.
The proportion of patients with CMC, bacterial vaginosis, or
cell atypia was similar in the two study visits approximately 25
years apart. Currently, four patients (21%) had C. albicans
growth either in vulva or vagina. In one of them, C. albicans
was resistant to fluconazole and voriconazole but sensitive to
amphotericin B and micafungin. The patient was using
prophylactic oral fluconazole. Three other C. albicans strainsFrontiers in Endocrinology | www.frontiersin.org 6were sensitive to fluconazole. Three of the four patients with C.
albicans had abnormal findings in gynecological examination;
one patient had clinical suspicion of candidiasis, one had
hypoestrogenic vulvar mucosa, and one had clinical
vulvovaginitis. None of them had cell atypia in the pap smear.
Two patients (11%) had been vaccinated against HPV. HPV
was found in five patients (26%); three (16%) had high-risk
subtypes 31, 33, 52 or 68; one of them had three of these
subtypes. Cell atypia (low-grade squamous intraepithelial
lesion) in Pap smear was detected in one patient whose HPV
test remained negative. Patients with bacterial vaginosis were
clinically asymptomatic.Autoantibodies to Cytokines
Autoantibodies against IFN-a or IFN-g were positive in all 19
patients. IL-17A, IL-17F, and IL-22 autoantibodies were found in
five, ten, and ten patients, respectively while six (32%) patients
had no other cytokine autoantibodies (Figure 2). The total
amount of positive anti-cytokine autoantibodies did not differ
considerably in correlation with age and presence of POI or PAI
(p >0.05). There was no difference in the prevalence of any
measured autoantibody according to the prevalence of any
genital infection (C. albicans, HPV, bacterial vaginosis; Fisher’s
exact test, p >0.05).TABLE 3 | Previous and current gynecological infections and pap smear findings in 19 patients with APECED.
Variable n %
Previous gynecological infections
C. albicans infections 17 89%
Bacterial vaginosis 5 26%
Condyloma 3 16%
Chlamydia 1 5%
History of abnormal pap smears a 7 37%
Gynecological visits in 1995 (11/19) b
Oral anti-fungal medication c
No 8 73%
Therapeutic dose 3 27%
Prophylactic dose – –
Genital C. albicans infection 3 27%
Bacterial vaginosis 2 18%
Cell atypia in pap smear 1 9%
Current infections and gynecological findings c
Oral anti-fungal medication d
No 15 79%
Therapeutic dose 3 16%
Prophylactic dose 1 5%
Genital C. albicans infection 4 21%
Only vulva 2 11%
Vulva and vagina 2 11%
HPV test (19/19)
Positive 5 26%
High-risk subtype 3 60%
Pap smear (19/19)
Bacterial vaginosis 2 11%
No cell atypia 18 95%
Cell atypia 1 5%November 2021 | Volume 12 | Article 78aCell atypia ASCUS or more/class 2 or higher; b11 patients participated in a gynecologic study also in 1995; cFrom the gynecological visits in 2019-20; dOnly systemic anti-fungal
medication was used.4195
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We carried out a comprehensive evaluation of 19 female patients
with APECED to clarify how endocrinopathies and
immunodeficiency affect the gynecologic health. In summary,
POI was diagnosed in 84% of the patients and 88% of them
currently used or had used until physiologic menopause
adequate HRT. In most of the women, the morphology and
size of the uterus were determined normal for age, menopausal
status, and current hormonal therapy. On the contrary to POI, of
the 15 patients with PAI, 73% had unmeasurable androgen levels
but only three used DHEA substitution. Genital infections were
found in almost half of the patients. Genital C. albicans infection
was diagnosed in four (21%) and HPV infection in five patients
(26%). Cervical cell atypia was detected only in one patient.
Measured anti-cytokine autoantibodies did not correlate with
any of the considered genital infections.
POI was diagnosed in most cases after spontaneous
menarche. However, 26% of the patients developed POI early
and had primary amenorrhea. AMH values were unmeasurably
low in 88% of POI subjects but could be detected in two patients
with POI. This represents a typical finding in POI with
steroidogenic cell autoimmunity where the pool of growing
follicles can initially remain intact (31). Thus, fluctuating
ovarian function is typically associated with the early phases of
POI and occasional ovulation may happen highlighting the
importance of contraception if needed. Early detection ofFrontiers in Endocrinology | www.frontiersin.org 7ovarian insufficiency is important to ensure timely pubertal
development and adequate growth of uterus with sufficient
HRT (32). In our series, the morphology and size of the uterus
were determined normal in 76% of women. In case of
dyspareunia or genitourinary symptoms, vulvovaginal atrophy
should be actively treated by local estrogens (33).
PAI is one of the three classic manifestations of APECED. In
our cohort, 15 women had PAI and all also suffered from POI.
All androgens were below the detection limit in 73% of the
patients with PAI. Because of abnormal hormonal function of
both the adrenal cortex and the ovaries, female patients with PAI
and POI do not have any normal production of androgens. In
our cohort, none of the patients currently used testosterone
substitution and only four patients had ever used testosterone,
three of them for induction of pubarche. Small case series have
shown long-acting testosterone to be effective in the induction of
pubarche (34). The only evidence-based indication for
testosterone therapy in women is for the hypoactive sexual
desire disorder. Effects of testosterone replacement therapy on
musculoskeletal health, overall wellbeing and cognition are not
clear (34, 35). Only three of the 15 patients with PAI used DHEA
substitution. Reported effects of DHEA substitution in PAI are
variable; some cohorts show significant improvements in sexual
health and libido (18) while others show no effect (19). In a small
series of adolescent girls with PAI, DHEA was beneficial to
induce pubarche and to relieve psychological distress (36).
However, current PAI guidelines do not recommend DHEAFIGURE 2 | The number of positive anti-cytokine autoantibodies (IFN-a, IFN-g, IL17A, IL17F, IL22) in the 19 female patients with APECED in relation to age group,
premature ovarian insufficiency (POI), human papillomavirus infection (HPV), candidiasis (CMC), bacterial vaginosis (BV), and cervical cell atypia. Age groups: 1, <20;
2 20–29; 3, 30–39; 4, 40–49; 5, 50–59; 6, 60–69 years.November 2021 | Volume 12 | Article 784195
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Regarding patients with POI, the effect of DHEA substitution
in the improvement of fertility and successful pregnancies is
controversial (38). Nevertheless, since POI often presents with
PAI in patients with APECED, DHEA replacement trial could be
beneficial in patients with low androgen levels due to both POI
and PAI. DHEA substitution in females with PAI may also have
positive effects on bone density (19). Further studies are needed
to evaluate the potential benefits of DHEA replacement in
women with APECED.
In APECED, the reported incidence of CMC at the oral
mucosa and other parts of the digestive tract varies between
77% and 100% (6). In an American APECED cohort the
prevalence of C. albicans in the genital tract was 52% (15). In
our cohort the prevalence was significantly lower as only 21-27%
of the females with APECED had C. albicans growth in the
genital tract cultures in the present or an earlier study visit.
Hypoparathyroidism has also been shown to associate with
impaired immune function. Symptoms and clinical findings
varied from asymptomatic to ulcerative and infectious mucosa
highlighting the importance of microbiological diagnosis. One of
the patients had currently C. albicans strain resistant to two
tested azoles. Even though the current prevalence of C. albicans
infections in the genital tract was not high, drug resistance might
appear and should be evaluated especially in chronic and
recurrent cases.
C. albicans is often seen as a commensal microbe at the
epithelial surfaces of a healthy individual but can become
pathogenic when immunity is compromised (39). Protection
against C. albicans is thought to be mediated by T cells,
particularly by IL-17–producing Th17 cells (40). Th17 cells
also produce other interleukins, such as IL-22, that regulate
antimicrobial genes and maintain barrier integrity at the
epithelial surfaces (41). In patients with APECED, antibodies
against IL-17A and IL-17B have been shown to correlate with the
development of oral CMC (7, 8). We did not find any correlation
between genital tract CMC or other genital infections and the
appearance of anti-cytokine autoantibodies. A very recent study
suggested that susceptibility to oral CMC is not due to impaired
IL-17 immunity in APECED but rather the infiltration of
malfunctioning CD4+ and CD8+ T cells in the oral mucosa.
These pathogenic T cells cause an excessive IFN-g/STAT1-
response that promotes oral epithelial defects and receptivity
for CMC (42). It is not known if a similar autoimmune process is
present in other mucosal surfaces in APECED.
In addition to CMC, hormonal deficiencies and defects in
mucosal barrier may increase the risk for other infections, as
genital infections were found in almost half of our patients. HPV
was found in five patients (26%) at the median age of 52 years,
and three of them (60%) had high-risk subtypes. The Finnish
series of women attending HPV screening during 2003–2005
showed HPV positivity to vary between 2.8–24.2% depending on
the age group and prevalence of high-risk subtypes to be 41.2–
65.5%. HPV positivity in 50-year-old female patients was 5.1%
(43). Based on this, HPV infection was over five times more
common in our cohort of females with APECED than in theFrontiers in Endocrinology | www.frontiersin.org 8average Finnish females. HPV infections are known to be more
likely to cause cell atypia when the patient has disturbances in
immune defense. Even though mutations in AIRE cause changes
in the T cell functions, we did not see a particularly high
incidence of cell atypia in patients with HPV. However, HPV
vaccinations could be considered to diminish the incidence of
high-risk HPV infections in patients with APECED.
Our study was limited by the small number of patients.
Nevertheless, it is noteworthy that our study is the largest
gynecologic evaluation ever performed in patients with
APECED and the participation rate (61%) was good.
Hormonal defects, mucosal health, and even asymptomatic
gynecologic infections may impair sexual wellbeing, but
without standardized questionnaires, we were not able to study
such effects.
In conclusion, APECED predisposes to sex hormone
deficiencies and genital infections. The high prevalence of POI
and PAI together with immunodeficiency in patients with
APECED warrant careful gynecological follow-ups to ensure
adequate HRT and treatment of genital infections. As POI is
commonly presented together with PAI, all androgens are often
very low in patients with APECED. The effects of DHEA
substitution on gynecologic well-being should be further
explored. Genital infections in female patients with APECED
are common and therefore low threshold of taking microbe
samples when symptoms are presented, are warranted. The
possibility of azole-resistant C. albicans strains should be
considered when prescribing medications for genital
candidiasis. Further studies are needed to explore the
mechanisms leading to increased risk for gynecologic infections.DATA AVAILABILITY STATEMENT
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